In 85% of patients worldwide, gastric cancer (GC) metastasizes from the very beginning or within three years. In 30–50% of cases, metastases, both synchronous and metachronous, grow into liver. Multifocal liver metastases translate into an unfavorable prognosis: the median survival period is 10–15 months, with less than 10% of the patients surviving past three years. In such cases, the palliative treatment option is systemic chemotherapy. Combined with immunotherapy, transarterial chemoembolization (TACE), a relatively new method of local treatment of metastatic foci, offer new options of combating liver metastases. This work presents a clinical case of application of this combination coupled with chemotherapy to treat a patient with unresectable liver metastases spawned by HER2⁺ gastric adenocarcinoma. From the day of diagnosis, the patient's life expectancy was 42 months.